Johnson & Johnson said sales of its key arthritis treatment, Remicade, slipped 16% from last year, pressuring overall revenues and clouding a fourth quarter earnings beat.
Johnson & Johnson Tops Q4 Earnings Forecast, But Light Revenue, Remicade Sales Hit Shares
Johnson & Johnson Tops Q4 Earnings Forecast, But Light Revenue, Remicade Sales Hit Shares
Leave a reply